

12 August 2025

Botanix presents at Canaccord Genuity Annual Growth Conference

Philadelphia and Phoenix US, 12 August 2025: Clinical dermatology company Botanix Pharmaceuticals Limited (ABN 70 009 109 755) (ASX:BOT, “Botanix” or “the Company”) is pleased to announce that their Chief Executive Officer Dr Howie McKibbin will be a featured presenter on Wednesday 13 August at the Canaccord Genuity 45th Annual Growth Conference in Boston, MA. This conference attracts hundreds of institutional fund managers from around the world, and some of the most promising global growth companies, including those in the healthcare and life sciences sectors, will present during the event.

A copy of the Company’s presentation is attached to this press release.

This ASX announcement is authorised for release by the Board.

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX: BOT) is a dermatology company based in Philadelphia and Phoenix (US), which has received FDA approval for its lead product *Sofdra* for the treatment of primary axillary hyperhidrosis. *Sofdra* is the first and only new chemical entity approved by FDA to treat primary axillary hyperhidrosis and presents a novel safe and effective solution for patients who have lacked treatment options for this socially challenging medical condition.

To learn more, please visit: <http://www.botanixpharma.com/>

For more information, please contact:

General enquiries

Corporate Communications

Botanix Pharmaceuticals

P: +61 8 6555 2945

investors@botanixpharma.com

Investor enquiries

Hannah Howlett

WE Communications

P: +61 450 648 064

hhowlett@we-worldwide.com

Media enquiries

Haley Chartres

H^CK

P: +61 423 139 163

haley@hck.digital


Cautionary Note on Forward-Looking Statements

Forward-looking statements can generally be identified by the use of forward-looking words such as, “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target” “outlook”, “guidance” and other similar expressions and include, but are not limited to, plans and prospects for the Company, the Company’s strategy, future operations, the expected timing and/or results of regulatory approvals and prospects of commercialising product candidates or research collaborations with its partners, including in Japan, the outcome and effects of *Sofdra* and the market for *Sofdra*. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements. The

For personal use only

forward-looking statements contained in this announcement are not indications, guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of Botanix, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. Investors should consider the forward-looking statements contained in this announcement in light of those disclosures and not place undue reliance on such statements. Except as required by law or regulation, Botanix undertakes no obligation to update forward-looking statements.

For personal use only



Botanix Pharmaceuticals Corporate Presentation

Canaccord Genuity 45th Annual Growth Conference

Important Notices & Disclaimer

1. Summary information

The following notice and disclaimer applies to this investor presentation (“Presentation”) and you are therefore advised to read this carefully before reading or making any other use of this Presentation or any information contained in this Presentation. By accepting this Presentation, you represent and warrant that you are entitled to receive this Presentation in accordance with the restrictions, and agree to be bound by the limitations, contained within it. This Presentation is dated 12 August 2025 and has been prepared by Botanix Pharmaceuticals Limited (ABN 70 009 109 755) (“Botanix” or “the Company”). The information contained in this Presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in evaluating a possible investment in the Company or that would be required in a prospectus or product disclosure statement prepared in accordance with the requirements of the Corporations Act 2001 (Cth). The information contained in this Presentation is a summary only and should be read in conjunction with the Company’s other periodic and continuous disclosure announcements lodged with the Australian Securities Exchange (“ASX”), which are available at www.asx.com.au.

2. Not an offer

Each recipient of this Presentation should make its own enquiries and investigations regarding all information in this Presentation including but not limited to the assumptions, uncertainties and contingencies which may affect future operations of the Company and the impact that different future outcomes might have on the Company and form their own views as to what information is relevant to such decisions and made their own investigations in relation to any additional information. This Presentation does not constitute investment or financial product advice (nor tax, accounting or legal advice) or any recommendation to acquire shares and does not and will not form any part of any contract for the acquisition of shares. Information in this Presentation is not intended to be relied upon as advice to investors or potential investors and has been prepared without taking account of any person’s individual investment objectives, financial situation or particular needs. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own investment objectives, financial situation and needs and seek legal, accounting and taxation advice appropriate to their jurisdiction. The Company is not licensed to provide financial product advice in respect of its securities.

3. Not investment advice

This Presentation does not constitute or contain an offer, invitation, solicitation or recommendation to subscribe for, acquire or sale of any securities in Botanix, or any other financial products or securities, in any place or jurisdiction. This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law or any other law and will not be lodged with the Australian Securities and Investments Commission. Persons who come into possession of this Presentation should observe any such restrictions as any non-compliance could contravene applicable securities laws.

4. Industry data

Certain market and industry data used in connection with or referenced in this Presentation has been obtained from public filings, research, surveys or studies made or conducted by third parties, including as published in industry-specific or general publications. Neither Botanix nor its advisers, or their respective representatives, have independently verified any such market or industry data.

5. Financial data

All dollar values are in United States dollars (\$) or US\$ unless otherwise stated. Amounts, totals and change percentages are calculated on whole numbers and not the rounded amounts presented.

6. Forward-looking statements and forecasts

This Presentation contains certain “forward-looking statements” and comments about future matters. Forward-looking statements can generally be identified by the use of forward-looking words such as, “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target” “outlook”, “guidance” and other similar expressions and include, but are not limited to, plans and prospects for the Company, the Company’s strategy, future operations, the expected timing and/or results of regulatory approvals and prospects of commercialising product candidates or research collaborations with its partners, including in Japan, the outcome and effects of Sofdra™ and the market for Sofdra™. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements. You are cautioned not to place undue reliance on forward-looking statements. Any such statements, opinions and estimates in this Presentation speak only as of the date hereof, are preliminary views and are based on assumptions and contingencies subject to change without notice, as are statements about market and industry trends, projections, guidance and estimates. Forward-looking statements are provided as a general guide only. The forward-looking statements contained in this Presentation are not indications, guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of Botanix, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. Any such forward-looking statements are also based on assumptions and contingencies which are subject to change and which may ultimately prove to be materially incorrect, as are statements about market and industry trends, which are based on interpretations of current market conditions. Investors should consider the forward-looking statements contained in this Presentation in light of those disclosures and not place undue reliance on such statements (particularly in light of the current economic climate and significant volatility). The forward-looking statements in this Presentation are not guarantees or predictions of future performance and may involve significant elements of subjective judgment, assumptions as to future events that may not be correct, known and unknown risks, uncertainties and other factors, many of which are outside the control of Botanix. Except as required by law or regulation, Botanix undertakes no obligation to finalise, check, supplement, revise or update forward-looking statements or to publish prospective financial information in the future, regardless of whether new information, future events or results or other factors affect the information contained in this Presentation. Certain data used in this Presentation have may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. It should be read in conjunction with Botanix’s other periodic and continuous disclosure announcement lodged with the ASX, which are available at www.asx.com.au or at <https://botanixpharma.com/invest/>

7. Disclaimer

The Company and its related bodies corporate and each of their respective directors, agents, officers, employees and advisers expressly disclaim, to the maximum extent permitted by law, all liabilities (however caused, including negligence) in respect of, make no representations regarding, and take no responsibility for, any part of this presentation and make no representation or warranty as to the currency, accuracy, reliability or completeness of any information, statements, opinions, conclusions or representations contained in this presentation. In particular, this Presentation does not constitute, and shall not be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of the Company.

This Presentation is authorised for release by the Board.

Corporate overview: Fast-growing dermatology pharmaceutical company with successful launch of lead product for hyperhidrosis

Dermatology Focused

Sofdra[™] is the first and only new chemical entity (sofpironium) to treat primary axillary hyperhidrosis

Innovative Platform

Fulfillment platform increases patient compliance and improves gross-to-net (GTN)

Strong Capital Position

\$64.9M
in cash and cash equivalents as of
June 30, 2025
(traded on ASX)
~\$300M Market Cap

Experienced Leadership Team

>30 dermatology products successfully launched

Driven by *Sofdra*[™], Botanix is committed to delivering dermatology solutions to patients with high unmet need

***Sofdra* (sofpironium) topical gel, 12.45%**



**FDA-approved treatment
for Primary Axillary
Hyperhidrosis in adult and
pediatric patients 9 years
of age and older¹**

Botanix acquired worldwide exclusive rights to sofpironium; patent protection through mid-2040

***Sofdra* approved by FDA in 2024 as the first new chemical entity for hyperhidrosis**

US Launch of *Sofdra*, February 2025, with strong uptake in a large, underserved market

Botanix leadership has a rich history of successful launch execution in dermatology



VINCE IPPOLITO
Executive Chairman



HOWIE MCKIBBON
Chief Executive Officer



CAREY HERBERT
Chief Legal & Compliance Officer



CHRIS LESOVITZ
Chief Financial Officer, U.S.



LEISHA MARTIN
VP, Quality, Regulatory & PV



PAUL SEABACK
Chief Technical Officer



MARTINA CARTWRIGHT
VP, Medical Affairs



>30
successful
dermatology
product
launches

*developed, secured
approval for, and
commercialized*

Three key pillars drive Botanix's near- and long-term value



**Strong Opportunity
for Lead Asset,
*Sofdra*TM**




**Differentiated
Fulfilment Platform**



**Clear Pathway to
Profitability and
Future Growth**

Hyperhidrosis is a medical condition characterized by excessive sweating

Hyperhidrosis patients have excessive sweating beyond what is needed to maintain normal body temperature¹



Hyperhidrosis Poses Day-to-Day Challenge for Patients¹⁻⁴



Frequently change clothes



Place napkins or pads under their arms or their pockets




Freshen up by wiping or bathing



Hide under dark-colored, bulky clothes

Many hyperhidrosis patients report **negative psychological impacts** including **persistent worry, disrupted social lives, heightened anxiety, and depression⁵**

Primary hyperhidrosis affects 2 times more patients than psoriasis and is the third largest patient category in dermatology



16.1M

PRIMARY HYPERHIDROSIS PATIENTS




7.5M

PSORIASIS PATIENTS²



Sofdra™ provides a targeted solution for patients

Sofdra binds selectively to M3 receptors in the sweat gland, blocks acetylcholine to inhibit sweat, and is rapidly metabolised¹



FDA-Approved Indication²

The treatment of primary axillary hyperhidrosis (PAH) in adults and pediatric patients 9 years of age and older

Efficacy²

High statistical significance across both co-primary endpoints: Patient Reported (HDSM-Ax-7) and Objective (GSP)

Safety and Tolerability²

Well-tolerated with adverse events that were mostly mild or moderate and transient; No serious TEAEs were reported

Proprietary Drug Delivery System

Applicator helps limit unwanted drug contact to hands during application and ensures consistent dosing



Sofdra™ is well positioned as a first-line prescription treatment



OTC

Degree Old Spice

CLINICAL STRENGTH

CERTAIN DRI ANTIPERSPIRANT SWEAT BLOCK

Sofdra™
(sofpironium) topical gel, 12.45%

ALUMINUM CHLORIDE

DRYSOL™

REFORMULATED ORAL DRUG INTO A SOLUTION

cuvposa.

REFORMULATED ORAL DRUG INTO A WIPE

Qbrexza®
(glycopyrronium) cloth

BOTOX INJECTION

BOTOX™
—Cosmetic
onabotulinumtoxinA

CUTTING NERVES


HEAT ENERGY DEVICE

miraDry®

In Sofdra™ phase 3 clinical trials, co-primary endpoints were highly statistically significant

≥2-point improvement in HDSM-Ax-7
from baseline to Day 43¹


Pooled Data (Cardigan 1 & 2)



HDSM-Ax scale measures patient reported severity of axillary (underarm) hyperhidrosis

GSP change from baseline
to Day 43¹

Pooled Data (Cardigan 1 & 2)




GSP (Gravimetric Sweat Production) is an objective measurement of underarm sweat production (mg/5 min)

A pooled analysis of two 6-week trials of Sofdra™ in severe to very severe patients

Pooled Data (Cardigan 1 and 2)

HDSM-Ax-7 reduction (≥1-point improvement) from baseline to end of treatment¹



Almost **85%** of *Sofdra* patients experienced a *statistically significant and clinically meaningful response*

Sources: 1. Data on file, Sofdra DOF, Botanix SB Inc.

In practice, Sofdra™ provides breakthrough relief for patients

“ My patient said this is the best treatment he’s ever used. Nothing has worked for him. He considered his sweating to be a 9/10. Now, after Sofdra, it’s a 1/10. ”

“ I’ve never used a specialty pharmacy that has been as seamless as SendRx. I put a prescription in on Friday afternoon and the patient had their medication by Saturday morning. ”


“ It’s great to have a new novel molecule that is a ‘topical gel’ with a unique applicator to treat PAH. You can tell a lot of thought went into it. Plus, ordering Sofdra is very straightforward, simple, and easy for us. Most importantly, it’s very easy on our patients. ”

“ In my opinion it’s a complete no-brainer. Free, little to no irritation, great efficacy, and little to no risk of getting it on their hands with the easy applicator use. So glad that my patients have a new option in this market that’s been underserved for years! ”

“ I had a patient who would discontinue their previous medication...in the winter time because he had bad irritation in the cold weather. I started him on treatment in early February and he already asked about a refill. ”

“ Sofdra is my new go to for HH. It’s nice to have a product that works well and is easy to get. You usually only get one or the other with pharmaceuticals. ”



The Botanix fulfilment platform removes the wholesaler, improving GTN yield and expediting fulfilment




GTN Deductions	Traditional Model	Botanix Model
Wholesale DSA	18%	N/A
Wholesale Prompt Pay	2%	N/A
Pharmacy Fee	0%	↑%
Managed Care	35%	≈%
Patient Rebate	30%	↓%
Reserves	3%	↓%
Returns	2%	N/A
Outcome	90% GTN	~60-70% GTN

30-40% GTN Yield

Botanix fulfilment platform provides several additional differentiated benefits



Sofdra™ total prescriptions (TRx) growing month over month




TRx Growth:
Q2 2025 vs. Q1 2025

+323.5%

Consistent growth in TRx driven by new patients and refill success

Undertaking sales force expansion due to high physician response


Feb 2025



of Sales Professionals


27

Oct 2025



50

Sofdra™ GTN yield has improved every month since launch with a target range of 30–40%



GTN Yield:
Month of June 2025

23%

Fulfilment platform continues to improve prior authorisation approval rates and the number of fully reimbursed prescriptions

ersonal use only

Botanix clear path to profitability



Strong Balance Sheet: As of 30 June 2025, Botanix had **\$64.9M in cash** and **\$15.3M in undrawn debt***



Operating Costs are Consistent and Stable: Inventory purchases are not anticipated in 1H FY2026



Rapidly Increasing Revenue: Revenue is projected to increase rapidly quarter on quarter, due to growth and expansion




Improving GTN: Month-over-month improvement in GTN yield is expected to continue — targeting 30–40% GTN

Botanix focus on sustained future value creation

1


Harvest Large Untapped Market



- ❖ Opportunity to activate 6.3M patients with Primary Axillary Hyperhidrosis
- ❖ Drive patients to integrated telemedicine platform

2

Platform Expansion through Mergers and Acquisitions



- ❖ Platform can be scaled to support additional future products
- ❖ Products that underperform in a traditional fulfilment model can realize immediate net sales growth with little or no up-front and marketing cost

3

Global Product Licensing



- ❖ Sofpironium was licensed to Kaken (Japan), and was launched in 2020 and then sublicensed to Dong Wha (Korea) in 2023
- ❖ Retain ability to license ex-US development and commercialization
- ❖ Income bolstered by up-front payments, royalties, and other deal features

Sources: 1. Glaser et al, HIS & JDD (2018); 2. Doolittle et. al., Arch Dermatol Res (2016); 3. Klick Sermo analysis 100 PCPs for HH (2024); 4. Klick Dermatologist interview; 5. Komodo claims data review 2015-2024